Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

973
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
973
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

633
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term quantitative CT trajectories of pulmonary Ground-Glass nodules during immune checkpoint inhibitor Therapy: A matched surveillance cohort study.

European journal of radiology·2026
Same author

Short-term quantitative CT changes in synchronous ground-glass nodules during immune checkpoint inhibitor therapy in patients with lung cancer.

Frontiers in immunology·2026
Same author

Trends in height and weight among children between 200304 and 202324 in Hong Kong Special Administrative Region, China.

Anthropologischer Anzeiger; Bericht uber die biologisch-anthropologische Literatur·2026
Same author

Upregulation of PpHsfB2b at high temperature represses light-induced anthocyanin biosynthesis in pear.

Plant physiology·2026
Same author

Dietary fructose promotes MASH/HCC progression through enhanced intestinal HIF-2α-dependent iron absorption.

bioRxiv : the preprint server for biology·2026
Same author

The Effect of Restrictive vs Liberal Blood Transfusion Strategy on Subsequent Myocardial Infarction Type.

JACC. Advances·2026

Related Experiment Video

Updated: Feb 24, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Circulating Prolidase Activity in Patients with Myocardial Infarction.

Adnan Sultan1, Yuting Zheng1, Patrick J Trainor2

  • 1Department of Medicine, Division of Cardiovascular Medicine, University of Louisville, Louisville, KY, United States.

Frontiers in Cardiovascular Medicine
|August 22, 2017
PubMed
Summary

Serum prolidase activity did not differ between acute myocardial infarction (MI) and stable coronary artery disease (CAD) patients. Further research is needed to explore the link between diabetes, prolidase activity, and MI risk.

Keywords:
acute myocardial infarctionatherothrombosiscoronary artery diseasediabetesprolidase

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

11.3K

Related Experiment Videos

Last Updated: Feb 24, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K
Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

11.3K

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Enzymology

Background:

  • Collagen integrity is crucial for atherosclerotic plaque stability.
  • Enzymes regulating collagen turnover, like prolidase, may indicate atherothrombosis risk.
  • Differences in prolidase activity could aid in diagnosing plaque rupture.

Purpose of the Study:

  • To investigate serum prolidase activity differences in patients with acute myocardial infarction (MI) versus stable coronary artery disease (CAD).
  • To compare prolidase activity between thrombotic and non-thrombotic MI subgroups.
  • To explore potential variations in prolidase activity related to diabetes in MI patients.

Main Methods:

  • Serum prolidase activity was measured in 15 stable CAD patients and 49 acute MI patients.
  • Activity was assessed at multiple time points: cardiac catheterization (T0), 6 hours post-presentation (T6), and follow-up (Tf/u).
  • Subgroup analyses included thrombotic vs. non-thrombotic MI and diabetic vs. non-diabetic MI patients.

Main Results:

  • Prolidase activity decreased over time in both acute MI and stable CAD groups (p < 0.0001).
  • No significant difference in prolidase activity was found between acute MI and stable CAD patients at any time point.
  • No significant difference was observed between thrombotic and non-thrombotic MI groups.
  • Preliminary data indicated lower prolidase activity in diabetic acute MI patients compared to non-diabetic counterparts (p = 0.02).

Conclusions:

  • Circulating prolidase levels do not significantly differentiate between acute MI and stable CAD.
  • Prolidase activity does not distinguish between thrombotic and non-thrombotic MI.
  • Further investigation is warranted to clarify the role of diabetes in modulating prolidase activity and its association with MI risk.